STAT
MARCH 12, 2024
Over the past year, I have watched many children die of measles. In the final stages, little lungs, filled with fluid and racked with inflammation, struggle for oxygen. The victims breathe faster and faster, gasping for air until, exhausted, they stop.
PharmaVoice
MARCH 15, 2024
The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Guardian - Pharmaceutical Industry
MARCH 10, 2024
Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier There was a sharp intake of breath last month when the pharmaceuticals group AstraZeneca cemented chief executive Pascal Soriot’s position as the best-paid FTSE 100 boss with a £17m pay package , up from £15.3m a year earlier.
BioPharma Dive
MARCH 14, 2024
Rezdiffra’s clearance is a turning point in the fight against the liver disease. But its sales potential is unclear, and competition could emerge from popular weight loss drugs.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
MARCH 12, 2024
DETROIT — Every morning, Rebecca Smith, nursing a surgically repaired knee, carefully walks down the hallway of her brutalist brick apartment building, takes the elevator one floor to the lobby, and negotiates the sharply angled driveway outside. There, she waits for an Uber to take her to the last place she wants to go: her methadone clinic.
PharmaVoice
MARCH 12, 2024
As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
MARCH 12, 2024
Discover why gut bacteria are considered the next frontier in medicine in this informative article. Learn about the importance of the microbiome, its impact on health, and how it relates to conditions like Clostridiales difficile.
STAT
MARCH 14, 2024
A new study suggests the antiviral drug obeldesivir may be effective in curing Ebola Sudan infections, for which there are currently no approved vaccines or treatments. Scientists at the University of Texas Medical Branch in Galveston tested the drug, made by Gilead, in primates, starting treatment 24 hours after the animals were given what should have been a lethal dose of Sudan ebolavirus by intramuscular injection.
PharmaVoice
MARCH 13, 2024
Biotech IPOs are off to the races in 2024, and investors are betting on horses that are derisked in targeted areas.
BioPharma Dive
MARCH 11, 2024
Publicly traded companies raised nearly $10 billion in follow-on stock offerings in January and February, a financing surge that’s driving a “sector recovery,” the investment bank said.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
MARCH 15, 2024
Popular mobile messaging apps that offer end-to-end encryption for their users' communications means that the content of messages is only accessible to the sender and the recipient. However, like any software, they still have potential cybersecurity risks and compliance concerns that users should be aware of - especially in pharma.
STAT
MARCH 11, 2024
UnitedHealth Group quietly acquired dozens of outpatient facilities in 2023, with a particular focus on surgery centers, according to a STAT review of company financial filings. Those acquisitions — nearly all of which the company never announced — build on the network of some 90,000 physicians UnitedHealth Group has amassed in recent years.
Outsourcing Pharma
MARCH 11, 2024
On March 7, Celadon Pharmaceuticals plc, a leading UK-based pharmaceutical company specializing in cannabis-based medicines, unveiled promising findings from an early economic analysis of its chronic pain clinical trial, dubbed CANPAIN.
BioPharma Dive
MARCH 15, 2024
The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.
pharmaphorum
MARCH 10, 2024
The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of the drug. Lilly said the US regulator “wants to further understand topics related to evaluating the safety and efficacy of donanemab,” which includes the safety and efficacy results of its pivotal TRAILBLAZER-ALZ 2 study.
STAT
MARCH 14, 2024
WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT. Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law , the Food and Drug
Pharma Times
MARCH 14, 2024
In the study, the Lymphoma Artificial Reader System accurately detected 90% of lymphatic cancers
BioPharma Dive
MARCH 12, 2024
Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.
pharmaphorum
MARCH 13, 2024
Transitioning patient-reported outcomes (PROs) from paper to digital (ePRO) is crucial for maintaining data integrity and improving the patient experience. Learn how to seamlessly make this transition and optimise your data collection process.
STAT
MARCH 13, 2024
As a boy growing up with hemophilia A, Noah Frederick reserved the end of his annual checkups to talk about new technologies. His doctor walked through various experimental approaches for the bleeding disorder and, invariably, gene therapy. It was coming, he always said, in your lifetime. Last year, it finally arrived. But Frederick, now a 23-year-old software engineer, isn’t sure he’ll get it.
Pharmaceutical Technology
MARCH 11, 2024
Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neuromuscular and blood disorders, are setting high expectations for the space in 2024.
BioPharma Dive
MARCH 14, 2024
The funding for the startup, which partnered with Bristol Myers Squibb last year, adds to a surge of recent investments in developers of antibody-drug conjugates.
pharmaphorum
MARCH 15, 2024
Explore the latest digital and supplier hires in the pharmaceutical industry, including Campbell, EMS Healthcare, PhRMA, and Exscientia in February 2024. Stay updated on the changing faces in industry.
STAT
MARCH 13, 2024
A series of new studies are raising hopes that CAR-T , a process in which treatments are made by genetically editing a patient’s own white blood cells, can eventually be used to treat an incurable and deadly type of brain cancer, called glioblastoma multiforme, or GBM. In the most dramatic result, from a three-person study conducted by researchers at Massachusetts General Hospital, a 72-year-old man saw his tumor shrink 18.5% in just two days and then decrease further over the next two mo
Pharmaceutical Commerce
MARCH 12, 2024
A qualitative study explores how these drugs are impacting these patients’ lives, while digging deeper into the possibility of deprescribing, with insight from primary care physicians.
BioPharma Dive
MARCH 11, 2024
Justin Klee and Joshua Cohen spoke to BioPharma Dive about the next steps for their company, which is considering pulling its only product from market after the drug failed a confirmatory study in ALS.
pharmaphorum
MARCH 12, 2024
Discover the latest agency, consultancy, and investor hires from February 2024, including personnel from OVID Health, Avalere, WE Communications, and Eurozeo. Stay updated with industry movements and key players.
STAT
MARCH 11, 2024
Despite being the largest minority in the nation , disabled people like us have been structurally and institutionally obstructed from entering research-dominated fields. When they do manage to break through, they are seldom given the support and accommodations needed to sustain employment and thrive in their professional lives. As we have experienced, including people with disabilities in academic leadership and decision-making positions can lead to innovation, creative problem-solving, and insi
Express Pharma
MARCH 12, 2024
The Government has rolled out the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024. This initiative, spearheaded by the Ministry of Chemicals and Fertilizers, seeks to curb misleading promotional activities and ensure responsible marketing practices within the sector. Some key features of UCPMP 2024 are: Ethical promotion: The UCPMP mandates that drug promotion must adhere to stringent ethical criteria.
BioPharma Dive
MARCH 14, 2024
Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with Wuxi-AppTec, a major contract manufacturer to the biopharmaceutical industry.
pharmaphorum
MARCH 12, 2024
In the latest episode of the pharmaphorum podcast, host Nicole Raleigh speaks (virtually) with Nathan Clark, founder and CEO of Ganymede, a modern data platform and Cloud infrastructure for science, to discuss the evolving role of the Cloud in biopharma and some rather revolutionary tools in AI drug discovery.
STAT
MARCH 15, 2024
A symphony of synapses fires every time a songbird sings. For Erich Jarvis, a neurobiologist at Rockefeller University, the neural pathways he finds particularly interesting inside a birds’ brain are those that enable the bird to make new sounds from listening to their environment. This is an ability known as vocal learning, and is perhaps most notably exhibited when a parrot mimics a person’s speech (or profanity).
Express Pharma
MARCH 11, 2024
The upcoming Pharma Industry Townhall by PharmaState Academy offers an array of insightful talks, panel discussions, and presentations. The details are as follows: Event Date: March 16, 2024 Location: Radisson Blu Marol Andheri Time: 09:00 AM – 05:00 PM The event aims to equip professionals with the latest knowledge and strategies crucial for navigating the industry’s changing dynamics.
BioPharma Dive
MARCH 11, 2024
Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.
pharmaphorum
MARCH 11, 2024
Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putting its accelerated approval in jeopardy.
Expert insights. Personalized for you.
364 
Let's personalize your content